| abstract |
The present invention is directed to a new class of 2-optionally substituted-4-piperazine-benzothiophene derivatives of the formula <IMAGE> Formula I in which Y is represented by hydrogen or C1-3 alkyl; R is represented by a substituent selected from the group consisting of hydrogen, C1-4 alkyl, C1-4 alkoxy, halogen, -CF3, -OCF3, and -OH; R1 is represented by hydrogen, cycloalkyl, C1-6 alkyl, phenyl optionally substituted, phenylalkyl, or phenylamidoalkyl; X is represented by hydrogen, -(CH2)nX1, CH=CHX1 or CHX2-(CH2)q -CH3; n is an integer from 0-2; q is either the integer 0 or 1; X1 is represented by -OH-,-OR2, -NR2R3, -CO2R2, -CONR2R3, -CN, or -COR2; R2 and R3 are each independently represented by hydrogen, C1-4 alkyl, phenyl optionally substituted, phenylalkyl, or R2 and R3 together form a (CH2)m cycloalkyl, where m=2- 6; X2 is -OR4 or -NR4R5 in which R4 and R5 are each independently hydrogen or C1-4 alkyl; and the pharmaceutically acceptable addition salts thereof; with the proviso that when n is O or X is -CH=CHX1, then X1 is not OH, OR2, or NR2R3; that are serotonin 5HT1A and 5HT1D receptor agents. |